Exscientia news
Collaborative efforts aim to accelerate drug discovery and improve clinical success
Agreement to utilize Exscientia’s AI-based capabilities and personalised medicine platform from target identification through patient selection
Research will be focused on up to 15 novel small molecule candidates across oncology and immunology
Exscientia will receive an upfront cash payment of $100 million with the potential of $5.2 billion in total milestones plus tiered r
Study shows benefit of the first AI-supported functional precision medicine platform to guide treatment selection and improve outcomes in patients with advanced haematological cancers
54% of patients demonstrated a clinical benefit of more than 1.3-fold enhanced progression-free survival compared to previous therapy
40% of patients experienced exceptional responses lasting at least three times longer than expected for their respective disease
VIENN
OXFORD, England--(BUSINESS WIRE)-- Exscientia plc (Nasdaq: EXAI), an AI-driven pharmatech company committed to discovering, designing and developing the best possible drugs in the fastest and most effective manner, today announced the closing of its previously-announced upsized initial public offering in the United States of 15,927,500 American Depositary Shares (“ADSs”) representing 15,927,500 ordinary shares, including 2,077,500 ADSs sold pursuant to the full exerc
OXFORD, England--(BUSINESS WIRE)-- Exscientia plc (Nasdaq: EXAI), an AI-driven pharmatech company committed to discovering, designing and developing the best possible drugs in the fastest and most effective manner, today announced the pricing of its upsized initial public offering in the United States of 13,850,000American Depositary Shares (“ADSs”) representing 13,850,000 ordinary shares at an initial public offering price of $22.00 per ADS, for total gross proceeds
- Four-year agreement with Bill & Melinda Gates Foundation to discover and develop small molecule therapeutics with less susceptibility to variants and greater patient access than current approaches --
- Exscientia to use leading AI platform and in-house drug expertise to discover and develop five phase 1-ready assets; Gates Foundation to contribute sector expertise in antivirals and global public health --
- Investment accelerates Exscientia’s Mpro coronavirus
First candidate in multi-target collaboration to reach in-license milestone
BMS to take responsibility for clinical and commercial development
Exscientia receives $20 million option exercise fee with additional development milestones as well as tiered royalties on product sales
OXFORD, U.K. – August 18, 2021 – Exscientia, a clinical-stage, artificial intelligence (AI)-driven pharmatech company,
Combines Exscientia’s leading AI-driven drug identification and design capabilities with GT Apeiron’s expertise in cyclin-dependent kinase (CDK) targets for oncology.
Expands existing CDK7 drug discovery partnership with additional CDK targeting drugs
Oxford & Shanghai – July 21st, 2021 – Exscientia, an AI-driven pharmatech company with a mission to revolutionise how drugs are discovered, and GT Apeiron Therapeutics (Apeiron), a Sh
Company’s technologies and drug-hunting expertise now responsible for world’s first and second AI-designed drugs to enter Phase I testing
Exscientia, a leading artificial intelligence (AI) driven pharmatech company, today announced the first AI-designed molecule for immuno-oncology to enter human clinical trials. The A2a receptor antagonist, which is in development for adult patients with advanced solid tumours, was co-invented and developed through a Joint Ventur